The rapid pace of cancer research regularly uncovers new oncogenic drivers, and even when a reliable molecular test exists, positive results are only meaningful when there is a corresponding therapeutic intervention. This is where Ignyta diverges from the market: our Rx/Dx platform provides a seamless match between data-backed drug candidates and CLIA-certified (and CAP, HIPAA, and QSR compliant) diagnostic tests to generate clear, actionable results for your patients.
But just how does Ignyta’s Rx/Dx approach translate to better patient care and better patient outcomes?
Ignyta’s Rx Capability and Our Precision Medicine Pipeline
By illuminating the exact molecular alterations that are fueling patients’ individual cancer types, we can match them with molecularly targeted treatments specifically aimed at stopping their disease in its tracks.
Ignyta’s R&D team has a proven record of developing drugs that work in disease models and in real life. Here’s a snapshot of current Phase I data for our flagship drug candidate, entrectinib: